Except renal replacement therapy, researchers reported potential drugs such as empagliflozin (5), sirtuins 3 (SIRT3) (6), linagliptin (7), rho-associated kinase (ROCK) inhibitors (8), mineralocorticoid receptor antagonist (9), and peptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) (10) could reduce the progression of DN in diabetic patients. The gene discussed is SIRT3; the disease is liver dysplastic nodule.